High levels of soluble serum hemojuvelin in patients with congenital dyserythropoietic anemia type I

European Journal of Haematology

Volumn 90, Issue 1, 2013, Pages 31-36

  Shalev, Hanna ^a   Perez Avraham, Galit ^a   Kapelushnik, Joseph ^b   Levi, Itai ^a   Rabinovich, Anat ^a   Swinkels, Dorine W ^c   Brasse Lagnel, Carole ^d   Tamary, Hannah ^e  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Congenital dyserythropoietic anemia; Hemojuvelin; Iron overload

Indexed keywords

ERYTHROPOIETIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOJUVELIN; HEPCIDIN; SOLUBLE HEMOJUVELIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE 1; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IRON OVERLOAD; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WESTERN BLOTTING;

ADULT; ANEMIA, DYSERYTHROPOIETIC, CONGENITAL; ANTIMICROBIAL CATIONIC PEPTIDES; CASE-CONTROL STUDIES; ERYTHROPOIESIS; FEMALE; FERRITINS; GPI-LINKED PROTEINS; HUMANS; IRON; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84871196456     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12027     Document Type: Article

References (25)

1. Heimpel H, Wendt F. Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta 1968;34:103-15.
2. Wickramasinghe SN, Wood WG. Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Haematol 2005;131:431-46.
3. Dgany O, Avidan N, Delaunay J, et al. Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet 2002;71:1467-74.
4. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006;91:727-32.
5. Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia. Hematol Oncol Clin North Am 2010;24:1089-107.
6. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-101.
7. Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, Swinkels DW, Tanno T, Miller JL. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008;112:5241-4.
8. Casanovas G, Swinkels DW, Altamura S, Schwarz K, Laarakkers CM, Gross HJ, Wiesneth M, Heimpel H, Muckenthaler MU. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med 2011;89:811-6.
9. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
10. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005;106:2884-9.
11. Kautz L, Nemeth E. Novel tools for the evaluation of iron metabolism. Haematologica 2010;95:1989-91.
12. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008;111:924-31.
13. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-71.
14. Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, Camaschella C. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 2012;119:5021-9.
15. Maxson JE, Chen J, Enns CA, Zhang AS. Matriptase-2- and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression. J Biol Chem 2010;285:39021-8.
16. Lakhal S, Schodel J, Townsend AR, Pugh CW, Ratcliffe PJ, Mole DR. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J Biol Chem 2011;286:4090-7.
17. Brasse-Lagnel C, Poli M, Lesueur C, Grandchamp B, Lavoinne A, Beaumont C, Bekri S. Immunoassay for human serum hemojuvelin. Haematologica 2010;95:2031-7.
18. Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, Theurl I, Hubalek M, Dieplinger H, Tselepis C, Ward DG, Vogel W, Zoller H. Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells Mol Dis 2012;48:233-7.
19. Rumjon A, Sarafidis P, Brincat S, Musto R, Malyszko J, Bansal SS, Macdougall IG. Serum hemojuvelin and hepcidin levels in chronic kidney disease. Am J Nephrol 2012;35:295-304.
20. Shalev H, Kapelushnik J, Moser A, Knobler H, Tamary H. Hypocholesterolemia in chronic anemias with increased erythropoietic activity. Am J Hematol 2007;82:199-202.
21. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 2008;3:e2706.
22. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clinl Chem 2010;56:1570-9.
23. Tamary H, Dgany O, Proust A, et al. Clinical and molecular variability in congenital dyserythropoietic anaemia type I. Br J Haematol 2005;130:628-34.
24. Fujikura Y, Krijt J, Necas E. Liver and muscle hemojuvelin are differently glycosylated. BMC Biochem 2011;21:52.
25. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-6.